Clinical Trial Update: Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating inotuzumab ozogamicin (CMC-544) in combination with rituximab in patients with B-cell non-Hodgkin lymphoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Besponsa (inotuzumab ozogamicin)
• Rituxan (rituximab)

Snippet

Sponsor: Pfizer | Conditions: B-Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-03-08